<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Medical Radiology and radiation safety</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Medical Radiology and radiation safety</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Медицинская радиология и радиационная безопасность</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">1024-6177</issn>
   <issn publication-format="online">2618-9615</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">45276</article-id>
   <article-id pub-id-type="doi">10.12737/1024-6177-2021-66-3-68-75</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Радиационная физика, техника и дозиметрия</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>Radiation physics, technology and dosimetry</subject>
    </subj-group>
    <subj-group>
     <subject>Радиационная физика, техника и дозиметрия</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">Analysis of the Physical and Radiobiological Equivalence of the Calculated  and Measured Dose Distributions for Prostate Stereotactic Radiotherapy</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>АНАЛИЗ ФИЗИЧЕСКОЙ И РАДИОБИОЛОГИЧЕСКОЙ ЭКВИВАЛЕНТНОСТИ  РАССЧИТАННЫХ И ИЗМЕРЕННЫХ ДОЗОВЫХ РАСПРЕДЕЛЕНИЙ  ДЛЯ СТЕРЕОТАКСИЧЕСКОЙ ТЕРАПИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Сухих</surname>
       <given-names>Е. С.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Sukhikh</surname>
       <given-names>E. S.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат физико-математических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of physical and mathematical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-1"/>
     <xref ref-type="aff" rid="aff-2"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Сухих</surname>
       <given-names>Л. Г.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Sukhikh</surname>
       <given-names>L. G</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>доктор физико-математических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of physical and mathematical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-3"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Вертинский</surname>
       <given-names>А. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Vertinsky</surname>
       <given-names>A. V.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-4"/>
     <xref ref-type="aff" rid="aff-5"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Ижевский</surname>
       <given-names>П. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Izhevsky</surname>
       <given-names>P. V.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-6"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Шейно</surname>
       <given-names>И. Н.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Sheino</surname>
       <given-names>I. N.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат физико-математических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of physical and mathematical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-7"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Верхотурова</surname>
       <given-names>В. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Vertoukhova</surname>
       <given-names>V. V.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-8"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">Томский областной онкологический диспансер</institution>
     <city>Томск</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">Tomsk Regional Oncology Center</institution>
     <city>Tomsk</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-2">
    <aff>
     <institution xml:lang="ru">Национальный исследовательский Томский политехнический университет, Томск</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University, Tomsk, Russia</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-3">
    <aff>
     <institution xml:lang="ru">Национальный исследовательский Томский политехнический университет</institution>
     <city>Томск</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University</institution>
     <city>Tomsk</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-4">
    <aff>
     <institution xml:lang="ru">Томский областной онкологический диспансер</institution>
     <city>Томск</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">Tomsk Regional Oncology Centre</institution>
     <city>Tomsk</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-5">
    <aff>
     <institution xml:lang="ru">Национальный исследовательский Томский политехнический университет</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-6">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-7">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-8">
    <aff>
     <institution xml:lang="ru">Национальный исследовательский Томский политехнический университет, Томск</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University, Tomsk, Russia</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <volume>66</volume>
   <issue>3</issue>
   <fpage>68</fpage>
   <lpage>75</lpage>
   <history>
    <date date-type="received" iso-8601-date="2021-07-20T00:00:00+03:00">
     <day>20</day>
     <month>07</month>
     <year>2021</year>
    </date>
   </history>
   <self-uri xlink:href="https://naukaru.ru/en/nauka/article/45276/view">https://naukaru.ru/en/nauka/article/45276/view</self-uri>
   <abstract xml:lang="ru">
    <p>Цель: Анализ физической и радиобиологической эквивалентности дозовых распределений, полученных при планировании гипофракционированного стереотаксического облучения предстательной железы и верификации трехмерным цилиндрическим дозиметром.&#13;
Материалы и методы: На основе анатомических данных 12 пациентов с диагнозом карциномы предстательной железы, стадии T2N0M0 с низким риском разработаны планы стереотаксической лучевой терапии с объемно-модулированным облучением (VMAT) в режиме облучения РОД 7,25 Гр за 5 фракций (СОД = 36,25 Гр) при номинальной энергии фотонного излучения 10 МВ. Разработанные планы верифицированы с использованием трехмерного цилиндрического фантома ArcCHECK. При этом измеряли трехмерное распределение дозы в фантоме, на основе которого с помощью программного обеспечения 3DVH рассчитывались значения трехмерного гамма-индекса и гистограммы доза–объём оконтуренных анатомических структур.&#13;
Следуя рекомендациям AAPM TG-218, критерием физической сходимости рассчитанного и измеренного дозового распределения было выбрано значение гамма-индекса γ (3 %, 2 мм, глобальная нормализация – ГН) при пороге, равном 20 % от дозового максимума плана и при совпадении точек не менее 95 %. Для анализа радиобиологической эквивалентности рассчитанного и измеренного дозового распределения использовались критерии вероятности локального контроля (TCP) и вероятности осложнений для нормальных тканей (NTCP), полученные на основе рассчитанных и измеренных гистограмм доза–объём. Для анализа использовались контуры мишени (PTV) и передней стенки прямой кишки. Для расчёта значений критериев TCP, NTCP использовался подход A. Niemierko, основанный на концепции равномерной однородной дозы (equivalent uniform dose, EUD).&#13;
Результаты: Результаты физической сходимости планов для всех пациентов по контуру «все тело» оказались выше 95% при критерии γ (3%, 2 мм, ГН). Сходимость по контуру PTV лежит в диапазоне (75,5-95,2)%. Величины TCP и NTCP, полученные на основе измеренных гистограмм доза–объем, оказались для всех пациентов выше запланированных значений. Показано, что в действительности ускоритель доставляет несколько более высокую дозу на контур PTV и переднюю стенку прямой кишки, чем планируется первоначально.&#13;
Заключение: Возможности современного дозиметрического оборудования позволяют перейти к верификации планов лечения на основе анализа радиобиологической эквивалентности на основе критериев TCP / NTCP с учётом индивидуальных особенностей пациента и возможностей оборудования для лучевой терапии.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>Purpose: Carrying out the analysis of the physical and radiobiological equivalence of dose distributions obtained during the planning of hypofractionated stereotactic radiation therapy of the prostate cancer and verification using a three-dimensional cylindrical dosimeter.&#13;
Material and Methods: Based on the anatomical data of twelve patients diagnosed with prostate carcinoma, stage T2N0M0 with low risk, plans were developed for stereotactic radiation therapy with volumetric modulates arc therapy (VMAT). The dose per fraction was 7,25 Gy for 5 fractions (total dose 36,25 Gy) with a normal photon energy of 10 MV. The developed plans were verified using a three-dimensional cylindrical ArcCHECK phantom. During the verification process, the three-dimensional dose distribution in the phantom was measured, based on which the values of the three-dimensional gamma index and the dose–volume histogram within each contoured anatomical structures were calculated with 3DVH software.&#13;
The gamma index value γ (3 %, 2 mm, GN) at a threshold equal to 20 % of the dose maximum of the plan and the percentage of coincidence of points at least 95 % was chosen as a criterion of physical convergence of the calculated and measured dose distribution according to the recommendations of AAPM TG-218. To analyze the radiobiological equivalence of the calculated and measured dose distribution, the local control probability (TCP) and normal tissue complication probability (NTCP) criteria were used based on the calculated and measured dose–volume histograms. Contours of the target (PTV) and the anterior wall of the rectum were used for the analysis. The approach based on the concept of equivalent uniform dose (EUD) by A. Niemierko was used to calculate the values of TCP/NTCP criteria.&#13;
Results: The results of physical convergence of plans for all patients on the contour of the whole body were higher than 95 % for the criteria γ (3 %, 2 mm, GN). The convergence along the PTV contour is in the range (75.5–95.2)%. The TCP and NTCP values obtained from the measured dose-volume histograms were higher than the planned values for all patients. It was found that the accelerator delivered a slightly higher dose to the PTV and the anterior wall of the rectum than originally planned.&#13;
Conclusion: The capabilities of modern dosimetric equipment allow us move to the verification of treatment plans based on the analysis of TCP / NTCP radiobiological equivalence, taking into account the individual characteristics of the patient and the capabilities of radiation therapy equipment.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>3D гамма-анализ</kwd>
    <kwd>гистограмма доза–объем</kwd>
    <kwd>локальный контроль опухоли</kwd>
    <kwd>вероятность лучевых повреждений нормальных тканей</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>3D gamma analysis</kwd>
    <kwd>dose-volume histogram</kwd>
    <kwd>tumor control probability</kwd>
    <kwd>normal tissue complication probability</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lo SS, Teh. BS, Lu JJ, et al. Stereotactic Body Radiation Therapy. Berlin Heidelberg, Springer-Verlag, 2012. 434 p. https://doi.org/10.1007/978-3-642-25605-9.</mixed-citation>
     <mixed-citation xml:lang="en">Lo SS, Teh. BS, Lu JJ, et al. Stereotactic Body Radiation Therapy. Berlin Heidelberg, Springer-Verlag, 2012. 434 p. https://doi.org/10.1007/978-3-642-25605-9.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ezzell GA, Burmeister JW, Dogan N, et al. IMRT Commissioning: Multiple Institution Planning and Dosimetry Comparisons. A Report from AAPM Task Group 119. Med. Phys. 2019;36 (XI):5359-5373.</mixed-citation>
     <mixed-citation xml:lang="en">Ezzell GA, Burmeister JW, Dogan N, et al. IMRT Commissioning: Multiple Institution Planning and Dosimetry Comparisons. A Report from AAPM Task Group 119. Med. Phys. 2019;36 (XI):5359-5373.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Smilowitz JB, Das IJ, Feygelman V, et al. AAPM Medical Physics Practice Guideline 5.a.: Commissioning and QA of Treatment Planning Dose Calculations- Megavoltage Photon and Electron Beams. J Appl Clin Med Phys. 2015,16(V):14-34. DOI: 10.1120/jacmp.v16i5.5768.</mixed-citation>
     <mixed-citation xml:lang="en">Smilowitz JB, Das IJ, Feygelman V, et al. AAPM Medical Physics Practice Guideline 5.a.: Commissioning and QA of Treatment Planning Dose Calculations- Megavoltage Photon and Electron Beams. J Appl Clin Med Phys. 2015,16(V):14-34. DOI: 10.1120/jacmp.v16i5.5768.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Miftena M, Olch A, Mihailidis D. Tolerance Limits and Methodologies for IMRT Measurement-Based Verification QA: Recommendations of AAPM Task Group No.218. Med. Phys. 2018;45(IV):e53-83.</mixed-citation>
     <mixed-citation xml:lang="en">Miftena M, Olch A, Mihailidis D. Tolerance Limits and Methodologies for IMRT Measurement-Based Verification QA: Recommendations of AAPM Task Group No.218. Med. Phys. 2018;45(IV):e53-83.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Nelms BE, Opp D, Robinson J, et al. VMAT QA: Measurement-Guided 4D Dose Reconstruction on a Patient. Med. Phys. 2012;39(8):4228-4238.</mixed-citation>
     <mixed-citation xml:lang="en">Nelms BE, Opp D, Robinson J, et al. VMAT QA: Measurement-Guided 4D Dose Reconstruction on a Patient. Med. Phys. 2012;39(8):4228-4238.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Olch AJ. Evaluation of the Accuracy of 3DVH Software Estimates of Dose to Virtual Ion Chamber and Film in Composite IMRT QA. Med. Phys. 2012;39(1):81-86.</mixed-citation>
     <mixed-citation xml:lang="en">Olch AJ. Evaluation of the Accuracy of 3DVH Software Estimates of Dose to Virtual Ion Chamber and Film in Composite IMRT QA. Med. Phys. 2012;39(1):81-86.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Вертинский А.В., Сухих Е.С., Сухих Л.Г. Верификация терапевтических планов с объёмной модуляцией интенсивности излучения // Медицинская физика. 2018. Т.78. №2. Т. 78. С. 12-20  [Vertinskiy AV, Sukhikh ES, Sukhikh LG. Verification of Therapeutic Plans with Volume Modulation of Radiation Intensity. Medical Physics. 2015;78(2):12-21 (In Russian)].</mixed-citation>
     <mixed-citation xml:lang="en">Vertinskiy A.V., Suhih E.S., Suhih L.G. Verifikaciya terapevticheskih planov s ob'emnoy modulyaciey intensivnosti izlucheniya // Medicinskaya fizika. 2018. T.78. №2. T. 78. S. 12-20  [Vertinskiy AV, Sukhikh ES, Sukhikh LG. Verification of Therapeutic Plans with Volume Modulation of Radiation Intensity. Medical Physics. 2015;78(2):12-21 (In Russian)].</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Gay HA, Niemierko A. A Free Program for Calculating EUD-based NTCP and TCP in External Beam Radiotherapy. Phys Med. 2007;23(3-4):115-25. DOI: 10.1016/j.ejmp.2007.07.001.</mixed-citation>
     <mixed-citation xml:lang="en">Gay HA, Niemierko A. A Free Program for Calculating EUD-based NTCP and TCP in External Beam Radiotherapy. Phys Med. 2007;23(3-4):115-25. DOI: 10.1016/j.ejmp.2007.07.001.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Paudel NR, Narayanasamy G, Han EY, et al. Dosimetric and Radiobiological Comparison for Quality Assurance of IMRT and VMAT Plans. Radiation Oncology Physics. 2017;18(5):237-244. https://doi.org/10.1002/acm2.12145.</mixed-citation>
     <mixed-citation xml:lang="en">Paudel NR, Narayanasamy G, Han EY, et al. Dosimetric and Radiobiological Comparison for Quality Assurance of IMRT and VMAT Plans. Radiation Oncology Physics. 2017;18(5):237-244. https://doi.org/10.1002/acm2.12145.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sumida I, Yamaguchi H, Kizaki H. Novell Radiological Gamma Index for Evaluation of 3-Dimentional Predicted Dose Distribution. Int J Radiat Oncol Biol Phys. 2015;92(4):779-86. DOI: 10.1016/j.ijrobp.2015.02.041.</mixed-citation>
     <mixed-citation xml:lang="en">Sumida I, Yamaguchi H, Kizaki H. Novell Radiological Gamma Index for Evaluation of 3-Dimentional Predicted Dose Distribution. Int J Radiat Oncol Biol Phys. 2015;92(4):779-86. DOI: 10.1016/j.ijrobp.2015.02.041.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sukhikh ES, Sukhikh LG, Taletsky AV, et al. Influence of SBRT Fractionation on TCP and NTCP Estimations for Prostate Cancer. Physica Medica. 2019;62:41-46. DOI: https://doi.org/10.1016/ j.ejmp.2019.04.017.</mixed-citation>
     <mixed-citation xml:lang="en">Sukhikh ES, Sukhikh LG, Taletsky AV, et al. Influence of SBRT Fractionation on TCP and NTCP Estimations for Prostate Cancer. Physica Medica. 2019;62:41-46. DOI: https://doi.org/10.1016/ j.ejmp.2019.04.017.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Levegrün S, Jackson A, Zelefsky M, et al. Risk Group Dependence of Dose-Response for Biopsy Outcome after Three-Dimensional Conformal Radiation Therapy of Prostate Cancer. Radiother Oncol. 2002;63(1):11-26. https://doi.org/10.1016/ S0167-8140(02)00062-2.</mixed-citation>
     <mixed-citation xml:lang="en">Levegrün S, Jackson A, Zelefsky M, et al. Risk Group Dependence of Dose-Response for Biopsy Outcome after Three-Dimensional Conformal Radiation Therapy of Prostate Cancer. Radiother Oncol. 2002;63(1):11-26. https://doi.org/10.1016/ S0167-8140(02)00062-2.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Dasu A, Dasu I. Prostate Alpha/Beta Revisited an Analysis of Clinical Results from 14168 Patients. Acta Oncol. 2012;51(8):963-74. https://doi.org/10.3109/0284186X.2012. 719635.</mixed-citation>
     <mixed-citation xml:lang="en">Dasu A, Dasu I. Prostate Alpha/Beta Revisited an Analysis of Clinical Results from 14168 Patients. Acta Oncol. 2012;51(8):963-74. https://doi.org/10.3109/0284186X.2012. 719635.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Cheung R, Tucker SL, Lee AK, et al. Dose-Response Characterictics of Low- and Intermediate-Risk Prosate Cancer Treated with External Beam Radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(4):993-1002.</mixed-citation>
     <mixed-citation xml:lang="en">Cheung R, Tucker SL, Lee AK, et al. Dose-Response Characterictics of Low- and Intermediate-Risk Prosate Cancer Treated with External Beam Radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61(4):993-1002.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Rana S, Cheng C, Zhao L, et al. Dosimetric and Radiobiological Impact of Intensity Modulated Proton Therapy and Rapidarc Planning for High-Risk Prostate Cancer with Seminal Vesicles. J Med Radiat Sci. 2017;64(1):18-24. https://doi.org/10.1002/ jmrs.175.</mixed-citation>
     <mixed-citation xml:lang="en">Rana S, Cheng C, Zhao L, et al. Dosimetric and Radiobiological Impact of Intensity Modulated Proton Therapy and Rapidarc Planning for High-Risk Prostate Cancer with Seminal Vesicles. J Med Radiat Sci. 2017;64(1):18-24. https://doi.org/10.1002/ jmrs.175.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Deasy J, Mayo C, Orton C. Treatment Planning Evaluation and Optimization should be Biologically and not Dose / Volume Based. Med Phys. 2015;42(6):2753-6. DOI: 10.1118/1.4916670</mixed-citation>
     <mixed-citation xml:lang="en">Deasy J, Mayo C, Orton C. Treatment Planning Evaluation and Optimization should be Biologically and not Dose / Volume Based. Med Phys. 2015;42(6):2753-6. DOI: 10.1118/1.4916670</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
